Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 2,503 shares of the business's stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $13.95, for a total transaction of $34,916.85. Following the completion of the sale, the insider now directly owns 164,363 shares of the company's stock, valued at approximately $2,292,863.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Soleil Boughton also recently made the following trade(s):
- On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.65, for a total value of $39,171.95.
- On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.17, for a total transaction of $965,130.57.
- On Friday, February 9th, Soleil Boughton sold 4,080 shares of Hims & Hers Health stock. The shares were sold at an average price of $10.03, for a total transaction of $40,922.40.
- On Monday, February 12th, Soleil Boughton sold 22,839 shares of Hims & Hers Health stock. The shares were sold at an average price of $10.03, for a total transaction of $229,075.17.
Hims & Hers Health Trading Down 2.4 %
READ THIS – If You Missed Out On The AI Boom
From Banyan Hill Publishing | Ad
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy.
Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Click on Adam's shiny forehead for more details.
Hims & Hers Health stock opened at $12.38 on Thursday. The firm's 50 day moving average price is $13.42 and its two-hundred day moving average price is $9.78. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $17.16.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. During the same period in the prior year, the business posted ($0.05) earnings per share. Hims & Hers Health's revenue for the quarter was up 47.4% compared to the same quarter last year. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.1 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on HIMS. Canaccord Genuity Group started coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They set a "buy" rating and a $20.00 price target for the company. Canaccord Genuity Group started coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a "buy" rating and a $20.00 target price on the stock. Jefferies Financial Group reissued a "hold" rating and issued a $15.00 price target (down from $17.00) on shares of Hims & Hers Health in a report on Tuesday. SVB Leerink began coverage on shares of Hims & Hers Health in a research note on Monday, February 26th. They issued a "market perform" rating and a $10.00 price objective on the stock. Finally, Leerink Partnrs reaffirmed a "market perform" rating on shares of Hims & Hers Health in a report on Monday, February 26th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $14.85.
Get Our Latest Analysis on Hims & Hers Health
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of HIMS. Graham Capital Management L.P. lifted its position in shares of Hims & Hers Health by 39.4% in the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company's stock worth $2,141,000 after buying an additional 96,277 shares during the last quarter. Swiss National Bank lifted its stake in shares of Hims & Hers Health by 9.2% in the third quarter. Swiss National Bank now owns 309,200 shares of the company's stock worth $1,945,000 after buying an additional 26,100 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company's stock worth $88,857,000 after buying an additional 428,671 shares during the period. Bank of New York Mellon Corp grew its stake in Hims & Hers Health by 11.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company's stock valued at $3,551,000 after buying an additional 58,288 shares during the last quarter. Finally, Must Asset Management Inc. acquired a new position in Hims & Hers Health in the 3rd quarter valued at $1,596,000. Institutional investors and hedge funds own 63.52% of the company's stock.
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
